Internal Review of FOI 23/882

Dear

As you will be aware, we've logged your email of 13 December 2023 regarding the response to FOI 23/882 as an internal review.

You have stated in your email below that the highlighted text on page 3 of the UKHSA document shows "*UKHSA recommending Oseltamir treatment immediately if the human patient meets case definition for avian influenza.*"

However, having checked the document that you attached, your statement is not correct, as this is not what the highlighted text on page 3 says. It says, "*Start oseltamivir treatment immediately if the patient meets case definition for avian influenza*."

To confirm, the UKHSA document you've attached says '**oseltamivir'** and not, as you've said in your email, '***Oseltamir***'. I have included a screenshot of the wording you highlighted to clarify this:


Start oseltamivir treatment immediately if the patient meets case definition for avian influenza. For guidance on dosage refer to UKHSA guidance (https://www.gov.uk/government/publications/influenza-treatment-and-prophylaxis-using-anti-viral-agents) on the use of antiviral agents for the treatment and prophylaxis of seasonal influenza.

The online version of the UKHSA document also refers to oseltamivir, not oseltamir:

https://www.gov.uk/government/publications/avian-influenza-guidance-and-algorithms-for-managing-human-cases/investigation-and-initial-clinical-management-of-possible-human-cases-of-avian-influenza-with-potential-to-cause-severe-human-disease

As stated in our response to FOI 23/882, the MHRA has granted Marketing Authorisations for Oseltamivir. Please find a link to the Public Assessment Report for Oseltamivir 30 mg, 45 mg and 75 mg hard capsules (PL 00142/1278-128) below: 5d2c770dfac07e0c8f8ffa0d3c1452690356945e (windows.net)

We hope that this provides the clarification you seek.

If you remain dissatisfied, you may ask the Information Commissioner (ICO) to make a decision on whether or not we have interpreted the FOIA correctly in dealing with the request and subsequent internal review. The ICO's address is:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF

Yours sincerely,

MHRA Customer Experience Centre
Communications and engagement team
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU